CRP–Albumin–Lymphocyte (CALLY) Index Is an Independent Prognostic Factor for Recurrent Esophageal Cancer After Curative Treatment
- 1Department of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan
- 2Department of Surgery, Yokohama City University, Yokohama, Japan
- 3Department of Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan
Abstract
Background/Aim: The C-reactive protein–albumin–lymphocyte (CALLY) index is a promising biomarker. We investigated the prognostic significance of the CALLY index in patients with recurrent esophageal cancer (EC).
Patients and Methods: Consecutive patients who developed recurrent EC after curative esophagectomy and received treatment for recurrence at Yokohama City University from 2005 to 2022 were selected based on medical records. The CALLY index was calculated as follows: serum albumin level (g/dl) × peripheral lymphocyte count (/μl)/[C-reactive protein level (mg/dl) × 104]. The primary endpoint was overall survival after recurrence. The secondary endpoint was the association between the CALLY index and the clinical course after recurrence, including the administration of first-, second-, and third- line treatments.
Results: One hundred patients were included in this retrospective study. The cut-off value for the CALLY index was set at 5. The 5-year overall survival rates were 11.2% and 46.9% for the low and high CALLY index groups, respectively (p<0.001). Multivariate analysis demonstrated that a low CALLY index was an independent prognostic factor for poor overall survival (hazard ratio=4.271, 95% confidence interval=2.370–7.696, p<0.001). Patients with a high CALLY index were significantly more likely to receive first-, second-, and third-line treatments than those with a low CALLY index.
Conclusion: The CALLY index may serve as a useful prognostic biomarker and may also be associated with the ability to receive subsequent lines of treatment in patients with recurrent esophageal cancer.
Related
- Treatment-dependent and independent prognostic value of inflammation-based nutritional indices in immune checkpoint inhibitor-based therapy for esophageal cancer
- Admission blood glucose and neutrophil-to-lymphocyte ratio provide independent and complementary prognostic value for in-hospital mortality in acute type A aortic dissection
- Treatment patterns and prognostic factors of radiation-associated esophageal fistula in patients with esophageal squamous cell carcinoma: a retrospective cohort study
- Joint neutrophil-to-lymphocyte ratio-systemic inflammation response index score as an independent prognostic biomarker for immunotherapy-treated intrahepatic cholangiocarcinoma.
- Treatment strategies for postoperative locoregional recurrent esophageal squamous cell carcinoma after curative resection: a narrative review
BibTeX
@article{takagi2026crpalbuminlymphocyte,
title = {{CRP–Albumin–Lymphocyte (CALLY) Index Is an Independent Prognostic Factor for Recurrent Esophageal Cancer After Curative Treatment}},
author = {MAKI TAKAGI and TORU AOYAMA and ITARU HASHIMOTO and TAIICHI KAWABE and YUKIO MAEZAWA and SHO SATO and KANECHIKA DEN and TAKASHI KOSAKA and TSUTOMU SATO and YOSUKE ATSUMI and MIKI KAYASHIMA and KOHEI SEKIGUCHI and AYAKO TAMAGAWA and KEISUKE KAZAMA and NOBUHIRO SUGANO and HARUHIKO CHO and NORIO YUKAWA and TAKAKI YOSHIKAWA},
journal = {In Vivo},
year = {2026},
month = oct,
doi = {10.21873/invivo.14518},
url = {https://doi.org/10.21873/invivo.14518},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - CRP–Albumin–Lymphocyte (CALLY) Index Is an Independent Prognostic Factor for Recurrent Esophageal Cancer After Curative Treatment
AU - MAKI TAKAGI
AU - TORU AOYAMA
AU - ITARU HASHIMOTO
AU - TAIICHI KAWABE
AU - YUKIO MAEZAWA
AU - SHO SATO
AU - KANECHIKA DEN
AU - TAKASHI KOSAKA
AU - TSUTOMU SATO
AU - YOSUKE ATSUMI
AU - MIKI KAYASHIMA
AU - KOHEI SEKIGUCHI
AU - AYAKO TAMAGAWA
AU - KEISUKE KAZAMA
AU - NOBUHIRO SUGANO
AU - HARUHIKO CHO
AU - NORIO YUKAWA
AU - TAKAKI YOSHIKAWA
PY - 2026
DA - 2026/10/29
JO - In Vivo
DO - 10.21873/invivo.14518
UR - https://doi.org/10.21873/invivo.14518
AB - Background/Aim: The C-reactive protein–albumin–lymphocyte (CALLY) index is a promising biomarker. We investigated the prognostic significance of the CALLY index in patients with recurrent esophageal cancer (EC). Patients and Methods: Consecutive patients who developed recurrent EC after curative esophagectomy and received treatment for recurrence at Yokohama City University from 2005 to 2022 were selected based on medical records. The CALLY index was calculated as follows: serum albumin level (g/dl) × peripheral lymphocyte count (/μl)/[C-reactive protein level (mg/dl) × 104]. The primary endpoint was overall survival after recurrence. The secondary endpoint was the association between the CALLY index and the clinical course after recurrence, including the administration of first-, second-, and third- line treatments. Results: One hundred patients were included in this retrospective study. The cut-off value for the CALLY index was set at 5. The 5-year overall survival rates were 11.2% and 46.9% for the low and high CALLY index groups, respectively (p<0.001). Multivariate analysis demonstrated that a low CALLY index was an independent prognostic factor for poor overall survival (hazard ratio=4.271, 95% confidence interval=2.370–7.696, p<0.001). Patients with a high CALLY index were significantly more likely to receive first-, second-, and third-line treatments than those with a low CALLY index. Conclusion: The CALLY index may serve as a useful prognostic biomarker and may also be associated with the ability to receive subsequent lines of treatment in patients with recurrent esophageal cancer.
SN - 0258-851X
SN - 1791-7549
ER -